Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Its Omnipod platform includes the Omnipod 5 automated insulin delivery system, which features a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor via Bluetooth; the Omnipod DASH insulin management system, which uses a Bluetooth-enabled pod controlled by a smartphone-like personal diabetes manager with a color touch screen; and the Omnipod Insulin Management System. The company also provides pods for Amgen's Neulasta Onpro kit, a delivery system intended to help reduce the risk of infection after intense chemotherapy. Insulet sells its products to end-users through the pharmacy channel and independent distributors. The company was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook
▼
Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.
This is a new legal development that adds to regulatory risk and could hurt investor confidence.
▼
Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.
This is a new guidance cut that directly reduces expected future revenue and earnings.
▼
JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.
This is a new analyst downgrade that directly impacts investor sentiment and valuation.
Q3 2026
▲2▼2
Insulet's innovation advances but safety, legal, and growth risks mount
▲
Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.
Highlights a key positive development that could support future revenue.
▲
Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.
Shows ongoing strong performance of the core product.
▼
FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.
A major regulatory setback with potential financial and reputational impact.
▼
Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.
Directly impacts investor expectations and stock valuation.
News & notes movingPODD
United States
PODD▼
Baron SMID Cap ETF Sells Insulet Stake Over Competition and Safety Concerns
Baron SMID Cap ETF sold its position in Insulet Corporation during the second quarter of 2026, according to the fund's quarterly investor letter. The fund said it exited the tubeless automated insulin delivery maker to re-evaluate an accelerating competitive landscape and to assess a series of safety issues affecting Insulet's AID production. Insulet has over 600,000 active global customers and reported $2.7 billion in revenues in 2025, a fraction of the $19 billion worldwide type 1 diabetes market it predicts for 2028, plus an additional $12 billion type 2 market in 2028. The fund said it admires the company and its products and is keeping Insulet on its radar. Insulet closed at $140.60 per share on September 16, 2026, down 4.27% over the past month and 57.84% over the past 52 weeks, with a market capitalization of $9.75 billion and a 52-week range of $126.40 to $354.88.
PODD · Competition · Negative Baron SMID Cap ETF exited Insulet over an accelerating competitive landscape in the tubeless automated insulin delivery market.
PODD · Supply · Negative The fund also cited a series of safety issues affecting Insulet's AID production as a reason for selling.
FDA Approves Abbott's First Wearable Dual Ketone and Glucose Monitor
The U.S. Food and Drug Administration on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older, making it the first wearable in the U.S. to continuously monitor ketone levels and the first global system to track blood sugar and ketones simultaneously in a single unit. The agency granted marketing authorization via the De Novo pathway for new low-to-moderate-risk devices, following a review of six clinical studies involving over 600 participants that demonstrated accurate tracking of clinically significant ketone variations. The sensor, which offers up to 10 days of wear, alerts users when ketones rise, replacing single-point urine or blood tests. Abbott is working with pump companies to integrate the sensor with automated insulin delivery systems, expecting compatibility with iLet from Beta Bionics Inc and twiist from Sequel Med Tech by the end of this year, and with systems from Insulet Corp and Tandem Diabetes Care Inc by 2027, alongside an exclusive integration with MiniMedGroup Inc for smart dosing systems. William Blair analyst Brandon Vazquez noted the clearance may create a new competitive dynamic for DexCom Inc shares, with the sensor likely most competitive in the pediatric population once integrated with AID pumps next year.
ABT · Technology · Positive FDA approves Abbott's first wearable dual glucose-ketone monitor, a new product/regulatory milestone for its Libre line.
MMED · Demand · Positive Abbott is working with MiniMedGroup on an exclusive integration of the Libre Duo sensor for smart dosing systems, a concrete product partnership.
Sequel Med Tech · Demand · Positive Abbott expects its Libre Duo dual ketone/glucose sensor to be compatible with Sequel Med Tech's twiist automated insulin delivery system by end of this year.
DXCM · Competition · Negative William Blair analyst notes Abbott's clearance may create a new competitive dynamic for DexCom shares, especially in pediatrics.
BBNX · Demand · Positive Abbott expects its new ketone sensor to be compatible with Beta Bionics' iLet automated insulin delivery system by year-end.
PODD · Demand · Positive Abbott plans integration of its new dual sensor with Insulet's automated insulin delivery systems by 2027.
Medication Adherence Market to Reach $15.35 Billion by 2035
The global medication adherence market is projected to grow from USD 6.08 billion in 2026 to USD 15.35 billion by 2035, at a compound annual growth rate of 10.92%, according to a new report from ResearchAndMarkets.com. The market's expansion is driven by rising chronic disease prevalence, an aging population, and adoption of digital health technologies. Software-centric solutions currently account for about 65% of the market, while hardware-centric solutions are expected to see faster growth. North America remains the largest regional market, with Asia-Pacific growing fastest. Key players include Medtronic, Roche, Insulet, Ypsomed, and 13 others.
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline
Insulet Corporation President and CEO Ashley McEvoy purchased 1,100 shares of common stock on August 21, 2026, in an open-market transaction valued at $162,217. The shares were acquired at prices ranging from $147.42 to $147.62, resulting in a weighted average purchase price of $147.47. Following the purchase, McEvoy directly holds 23,731 shares and indirectly holds 4 shares through a trust, bringing her total position to 23,735 shares valued at $3.52 million based on the August 21 closing price of $148.16. The company, which develops the Omnipod insulin delivery platform, reported trailing twelve-month revenue of $3.1 billion and net income of $375.3 million. Insulet's latest quarterly sales grew 23% year over year on a constant currency basis, and management expects full-year revenue growth of about 21%.
Insulet CEO and Directors Buy Shares Amid Product Correction
Insulet Corporation's CEO and two directors made significant insider stock purchases in 2026, even as the company faced a voluntary medical device correction for certain Omnipod pods. CEO Ashley McEvoy bought 4,300 shares in late February at an average price of $239.35, investing just over $1 million, while independent director Michael Minogue purchased 2,030 shares at $246.23, totaling about $499,800. Independent chair Elizabeth Weatherman bought roughly $497,000 worth of stock in early June at $144 per share, boosting her holdings by 66%. The company initiated a voluntary correction on May 26 for specific lots of Omnipod 5, Dash, and Eros pods due to a cannula tear that could cause insulin under-delivery, sending shares down over 5% to around $146. Insulet shares closed at $161.28 on August 12, down 11.78% over one month and 54.06% over 52 weeks, with a market capitalization of $11.17 billion.
JPMorgan downgrades Insulet to neutral, slashes price target to $152
JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight and slashed its price target to $152 from $275, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients, and a weaker-than-expected outlook for 2027. The brokerage removed the stock from its Analyst Focus List, arguing that decelerating new patient additions, higher Type 2 patient attrition, and looming competition in the patch pump market could weigh on growth. JPMorgan lowered its 2027 revenue forecast by 7.6% to $3.67 billion and cut its adjusted EPS estimate by 8.8% to $7.62, while making only modest changes to its 2026 forecasts. The firm said management's early commentary for 2027 appeared too optimistic and expects investors to remain cautious until growth stabilizes and earnings expectations are reset. International performance remained solid, supported by strong Omnipod adoption and expansion into markets such as Spain and Australia, but JPMorgan believes those positives are likely to be overshadowed by slowing U.S. growth and intensifying competition expected to emerge in 2027.
Insulet forecasts 2026 revenue growth of 20%-22% as it adjusts U.S. assumptions on type 2 retention
Insulet has updated its full-year 2026 revenue growth outlook to 20% to 22%, down from its prior forecast, citing lower-than-expected utilization and retention among type 2 diabetes customers in the U.S. The company reported second-quarter revenue of $802 million, beating analyst estimates, with adjusted earnings per share of $1.66. CEO Ashley McEvoy described the type 2 trends as an execution challenge, noting that more than 40% of new U.S. customer starts are people with type 2 diabetes but that retention and utilization rates have weakened. In response, Insulet is expanding its customer care team, changing sales force compensation to reward longer-term retention, refining sample deployment, and rolling out new technology platforms. The updated guidance assumes these type 2 trends persist through the second half of the year, with U.S. Omnipod revenue growth now seen at 17% to 19% and international revenue growth at 30% to 32%.
PODD · Demand · Negative Lower-than-expected utilization and retention among type 2 diabetes customers in the U.S. reduces demand for Omnipod, prompting a cut in 2026 revenue growth guidance.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines for PODD, MVST, HUBG
The Law Offices of Howard G. Smith reminds investors of upcoming lead plaintiff deadlines in securities fraud class actions against Insulet Corporation, Microvast Holdings, and Hub Group. For Insulet, the class period is February 21, 2025 to May 26, 2026, with a lead plaintiff deadline of August 31, 2026; the complaint alleges defective manufacturing controls and misleading statements. For Microvast, the class period is April 1, 2025 to March 16, 2026, with a deadline of September 21, 2026; the complaint alleges overstated margin targets and delays in the Huzhou Phase 3.2 expansion. For Hub Group, the class period is April 28, 2023 to May 11, 2026, with a deadline of August 28, 2026; the complaint alleges material misstatements in financial statements from Q1 2023 to Q3 2025. Investors who suffered losses may contact the firm to discuss their legal rights.
Frank R. Cruz Law Offices Reminds Investors of Class Action Deadlines for FUTU, HUBG, PODD, and PLAB
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Futu Holdings, Hub Group, Insulet Corporation, and Photronics. For Futu Holdings, the lead plaintiff deadline is August 25, 2026, with allegations that the company failed to disclose non-compliance with CSRC requirements and overstated financial results. Hub Group faces an August 28, 2026 deadline over claims of material misstatements in financial statements from Q1 2023 to Q3 2025. Insulet Corporation has an August 31, 2026 deadline, with allegations of defective manufacturing controls and safety regulation violations. Photronics has a September 4, 2026 deadline, with claims that the company failed to disclose severe bottlenecks in its high-end chip design release pipeline.
SueWallSt alerts Insulet investors to August 31 lead plaintiff deadline in securities class action
SueWallSt reminds Insulet Corporation investors that the lead plaintiff deadline for a pending securities class action is August 31, 2026. The lawsuit covers shareholders who purchased Insulet securities between February 21, 2025 and May 26, 2026, alleging the company made misleading statements about its manufacturing quality and product safety. Insulet's stock fell from approximately $236 to $146.01 after two Medical Device Corrections disclosed in March and May 2026, with the second affecting roughly 7 million Omnipod Pods across multiple product lines. The complaint also alleges that insiders sold $5.9 million in stock during the class period. Investors may contact SueWallSt, powered by Levi & Korsinsky LLP, for a no-cost case evaluation.
PODD · Regulation · Negative Securities class action alleging misleading statements about manufacturing quality and product safety, with stock drop and insider sales.
Rosen Law Firm Reminds Insulet Investors of August 31 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false and misleading statements about its manufacturing controls and procedures, which created a risk of product safety violations and investor damages when the truth emerged. Investors may be entitled to compensation through a contingency fee arrangement and can join the action by contacting the firm. Rosen Law Firm highlights its track record in securities class actions, including the largest-ever settlement against a Chinese company and over $438 million recovered for investors in 2019.
Rosen Law Firm reminds Insulet investors of August 31 lead plaintiff deadline in securities class action
Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false or misleading statements and failed to disclose defective manufacturing controls and procedures, which created a risk that products would violate safety regulations or cause injury. Investors who purchased Insulet securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record in securities class actions, including achieving the largest ever settlement against a Chinese company and recovering billions of dollars for investors.
S&P 500 August Returns Historically Strong When Year-to-Date Gains Are 5% to 13%
The S&P 500 Index has gained 8.5% year to date heading into August, a level that historically favors bullish August returns. Since 1975, August has been the third-worst month for the index with an average return of 0.21%, but when the year-to-date gain through July is between 5% and 13%, August has averaged a 1.78% return with positive results 77% of the time. The index spent July hovering just below its all-time high without breaking through, a pattern that has occurred 11 previous times and led to an average slight loss of 0.12% the following month, though a new high was reached 55% of the time. Over the past ten years, the August-September period has averaged a 0.4% loss for the S&P 500, yet certain stocks have consistently outperformed, including Insulet and Ross Stores, which beat the index in nine of those ten years.
Insulet investors face August 31 deadline in securities fraud class action over Omnipod safety
A securities fraud class action has been filed against Insulet Corporation and certain senior executives, with a lead plaintiff deadline of August 31, 2026. The lawsuit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented the safety of its Omnipod insulin delivery products and its manufacturing quality. On March 12, 2026, the company disclosed a manufacturing defect causing insulin under-delivery, triggering a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, covering Omnipod 5, Omnipod DASH, and Omnipod Eros systems, led to a further 5.07% decline from $218.11 to $146.01 per share. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP before the deadline to seek lead plaintiff appointment.
PODD · Regulation · Negative Securities fraud class action lawsuit alleging misrepresentation of Omnipod safety and manufacturing quality, with stock drops on disclosures.
Securities fraud lawsuit filed against Insulet Corporation over alleged manufacturing defects
A securities fraud class action lawsuit has been filed against Insulet Corporation on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made misleading statements by failing to disclose defective manufacturing controls and procedures, which created a heightened risk of product safety violations. On March 12, 2026, the company announced a voluntary Medical Device Correction for certain Omnipod 5 Pods, causing shares to fall 7% from $236.07 to $219.84. Then on May 26, 2026, another correction was disclosed for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, leading to a 5% drop from $153.80 to $146.01. Investors have until August 31, 2026 to seek lead plaintiff appointment through Kirby McInerney LLP.
Insulet Sued for Securities Fraud Over Omnipod Safety Misrepresentations
A class action lawsuit has been filed against Insulet Corporation for securities fraud related to the safety of its Omnipod insulin delivery products. The suit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented product safety and its manufacturing quality, concealing defects that risked patient health. On March 12, 2026, the company disclosed a manufacturing issue causing tears in the internal tubing of Omnipod 5 Pods, leading to a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, affecting Omnipod 5, Omnipod DASH, and Omnipod Eros systems, triggered a further 5.07% decline from $218.11 to $146.01 per share. Investors have until August 31, 2026 to seek lead plaintiff appointment.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against FUTU, HUBG, PODD, and PLAB
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Futu Holdings Limited, Hub Group, Inc., Insulet Corporation, and Photronics, Inc., with lead plaintiff deadlines ranging from August 25 to September 4, 2026. The complaint against Futu alleges the company made false or misleading statements by failing to disclose non-compliance with CSRC requirements, including conducting securities, public fund sales, and futures business in mainland China without proper licenses, which could lead to regulatory penalties and overstated financial results. Hub Group is accused of material misstatements in financial statements from Q1 2023 to Q3 2025 due to premature transaction recognition and understated costs. Insulet allegedly had defective manufacturing controls that created a risk of safety violations, while Photronics is said to have concealed severe bottlenecks in its high-end chip design release pipeline. Investors who suffered losses may contact the firm to discuss their legal rights.
FUTU · Regulation · Negative Futu Holdings is alleged to have failed to disclose non-compliance with CSRC requirements, including conducting unlicensed securities, public fund sales, and futures business in mainland China, leading to a securities fraud class action.
HUBG · Regulation · Negative Hub Group is accused of material misstatements in financial statements due to premature transaction recognition and understated costs, leading to a securities fraud class action.
PLAB · Regulation · Negative Photronics is alleged to have concealed severe bottlenecks in its high-end chip design release pipeline, resulting in a securities fraud class action.
PODD · Regulation · Negative Insulet is accused of having defective manufacturing controls that created a risk of safety violations, leading to a securities fraud class action.
Grabar Law Office Investigates Fiduciary Breach Claims Against Erasca, Insulet, Photronics, and Via Transportation
Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of Erasca, Insulet, Photronics, and Via Transportation. The Erasca probe concerns disclosures about its pan-RAS molecular glue candidate ERAS-0015, including alleged improper comparisons to Revolution Medicines' RMC-6236 and undisclosed intellectual property risks; on April 27, 2026, the company disclosed patent infringement allegations and preliminary Phase 1 data showing a patient death, after which its share price fell substantially. The Insulet investigation relates to manufacturing defects that led to voluntary Medical Device Corrections for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods on March 12 and May 26, 2026, due to a risk of insulin under-delivery. Photronics is being investigated over statements about strong demand for high-end IC photomask products that allegedly omitted stalled customer design releases caused by foundry utilization and cost pressures. The Via Transportation probe focuses on its September 15, 2025 IPO, with allegations that offering documents failed to disclose declining Platform Annual Run-Rate Revenue per customer and regulatory hurdles in Germany. Current long-term shareholders of each company may seek corporate governance reforms and damages through shareholder derivative actions at no personal cost.
ERAS · Regulation · Negative Investigation over alleged improper disclosures and patent infringement; share price fell after disclosure.
PLAB · Regulation · Negative Investigation over alleged omissions about stalled customer design releases due to foundry utilization and cost pressures.
PODD · Regulation · Negative Investigation over manufacturing defects leading to voluntary Medical Device Corrections for Omnipod products.
VIA · Regulation · Negative Investigation over alleged failure to disclose declining revenue per customer and regulatory hurdles in Germany at IPO.
Rosen Law Firm urges Insulet investors to secure counsel before August 31 lead plaintiff deadline
Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false and misleading statements and failed to disclose defective manufacturing controls and procedures, which created a heightened risk of safety violations or injury. Investors who purchased Insulet securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record in securities class actions, including the largest-ever settlement against a Chinese company and over $438 million recovered for investors in 2019 alone.
PODD · Regulation · Negative Securities class action lawsuit alleges Insulet made false statements and failed to disclose defective manufacturing controls, creating risk of safety violations or injury.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Class Actions Against Insulet, Photronics, and Planet Fitness
Holzer and Holzer LLC reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Insulet Corporation, Photronics Inc., and Planet Fitness Inc. The deadline for Insulet is August 31, 2026, for a case alleging misleading statements about manufacturing controls and procedures between February 21, 2025 and May 26, 2026. The deadline for Photronics is September 4, 2026, for a case alleging misleading statements about its high-end product pipeline and demand stability between December 10, 2025 and May 27, 2026. The deadline for Planet Fitness is September 14, 2026, for a case alleging misleading statements about its Black Card price increase rollout, membership growth, and marketing strategy between November 6, 2025 and May 6, 2026. Investors who purchased shares during the respective periods and suffered losses are encouraged to contact the firm.
Insulet investors face August 31 lead plaintiff deadline in securities fraud class action
Glancy Prongay Wolke & Rotter LLP reminds Insulet Corporation investors that the deadline to file a lead plaintiff motion in a securities fraud class action is August 31, 2026. The lawsuit covers investors who purchased or acquired Insulet securities between February 21, 2025 and May 26, 2026. The complaint alleges that the company made false and misleading statements and failed to disclose defects in its manufacturing controls, which created a risk of product safety violations. Two voluntary medical device corrections for Omnipod pods were announced in March and May 2026, causing stock price drops of 6.9% and 5.1% respectively.
Frank R. Cruz Law Offices Reminds Investors of Class Action Deadlines for FUTU, HUBG, PODD, and PLAB
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Futu Holdings, Hub Group, Insulet Corporation, and Photronics. For Futu Holdings, the lead plaintiff deadline is August 25, 2026, with allegations that the company failed to disclose non-compliance with CSRC requirements and overstated financial results. Hub Group faces an August 28, 2026 deadline over claims of material misstatements in financial statements from Q1 2023 to Q3 2025. Insulet Corporation has an August 31, 2026 deadline, with allegations of defective manufacturing controls that heightened the risk of safety violations. Photronics has a September 4, 2026 deadline, with claims that the company failed to disclose severe bottlenecks in its high-end chip design release pipeline.
Bronstein, Gewirtz & Grossman Files Class Action Against Insulet Alleging Securities Fraud
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Insulet Corporation and certain officers, alleging violations of federal securities laws. The suit seeks to recover damages for investors who purchased or acquired Insulet securities between May 21, 2025 and May 26, 2026. The complaint claims that defendants made materially false and misleading statements regarding the company's business, operations, and compliance policies, including defective manufacturing controls that created a heightened risk of safety violations or injury. Investors have until August 31, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.
Pomerantz Law Firm Files Class Action Against Insulet Over Alleged Securities Violations
Pomerantz LLP has filed a class action lawsuit against Insulet Corporation and certain officers on behalf of investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. The suit, filed in the US District Court for the District of Massachusetts, alleges that the company made false and misleading statements about its manufacturing controls and product safety. The complaint points to two voluntary medical device corrections disclosed in 2026—one on March 12 for Omnipod 5 Pods and another on May 26 for Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System Pods—which caused the stock to drop 6.88% and 5.07% respectively. Investors have until August 31, 2026 to seek appointment as lead plaintiff.
PODD · Regulation · Negative Class action lawsuit alleging false statements about manufacturing controls and product safety, with two product corrections causing stock drops.
Insulet Fell Along with Broad Medtech Sector, ClearBridge Says
Insulet Corporation detracted from performance in the second quarter of 2026 amid broad medtech weakness, a minor product recall, quality issues, and rising concerns around potential future competition, according to ClearBridge Investments' SMID Cap Growth Strategy. The strategy noted that weakness in provider and select medical technology holdings offset otherwise solid contributions from biotechnology and life sciences tools. Insulet, known for its Omnipod insulin delivery system, saw its shares lose 44.77% over the past 52 weeks, closing at $161.28 on July 10, 2026. The company generated revenue of $762 million in the first quarter of 2026, an increase of 34% on a reported basis.
Faruqi & Faruqi Reminds Insulet Investors of August 31, 2026 Securities Class Action Deadline
Faruqi & Faruqi, LLP reminds investors of the August 31, 2026 deadline to seek lead plaintiff in a securities class action against Insulet Corporation. The lawsuit alleges Insulet made false and misleading statements by failing to disclose defective manufacturing controls that created a heightened risk of product safety violations or injury. The truth began to emerge on March 12, 2026, when Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, causing its stock to drop 6.88% to $219.84 per share. Then on May 26, 2026, Insulet disclosed another correction for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, sending shares down 5.07% to $146.01. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 may be eligible to participate.
PODD · Regulation · Negative Securities class action lawsuit alleges Insulet made false statements about defective manufacturing controls, leading to product corrections and stock drops.
PODD Investors Can Lead Insulet Securities Fraud Lawsuit
The Schall Law Firm reminds investors of a class action lawsuit against Insulet Corporation for alleged securities fraud. The lawsuit covers investors who purchased Insulet securities between February 21, 2025 and May 26, 2026, with a lead plaintiff deadline of August 31, 2026. The complaint alleges Insulet made false and misleading statements about defective manufacturing controls and safety violations, and that a March 2026 Medical Device Correction impacted more Pod Products than disclosed. Investors who suffered losses are encouraged to contact the firm.
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of First Solar, Insulet, Photronics, and Via Transportation
Grabar Law Office is investigating claims on behalf of long-term shareholders of First Solar, Insulet Corporation, Photronics, and Via Transportation. The investigations concern whether certain officers and directors of each company breached their fiduciary duties. For First Solar, the probe follows a securities fraud class action alleging executives overstated the company's ability to manage U.S. tariff policy impacts and understated negative effects on fiscal 2026 performance. For Insulet, a class action alleges defective manufacturing controls led to voluntary medical device corrections for Omnipod products in March and May 2026. For Photronics, a class action alleges the company made misleading statements about strong demand for high-end IC photomasks while knowing customer design releases had stalled. For Via Transportation, a class action alleges IPO offering documents omitted that the company was adding customers faster than they generated revenue and that regulatory issues would hinder its German expansion strategy. Shareholders who purchased shares before specified dates and still hold them can seek corporate reforms and return of funds at no cost.
FSLR · Regulation · Negative Alleged securities fraud for misleading statements about managing U.S. tariff policy impacts and understating negative effects on fiscal 2026 performance.
PLAB · Demand · Negative Alleged misleading statements about strong demand for high-end IC photomasks while knowing customer design releases had stalled.
PODD · Supply · Negative Alleged defective manufacturing controls led to voluntary medical device corrections for Omnipod products.
VIA · Demand · Negative Alleged IPO omissions that company was adding customers faster than they generated revenue and regulatory issues would hinder German expansion.
Insulet Launches Omnipod 5 in Spain as Evercore ISI Cuts Price Target to $180
Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking its 20th market for Omnipod 5 and 26th country for Omnipod products. The expansion supports the company's goal of broadening access to its tubeless insulin delivery technology. Separately, Evercore ISI lowered its price target on Insulet to $180 from $200 while maintaining an Outperform rating, citing generally positive industry trends in its second-quarter MedTech preview.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Futu, Hub Group, and Insulet Class Actions
Holzer and Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Futu Holdings, Hub Group, and Insulet Corporation. The Futu lawsuit, covering purchases between May 24, 2023 and May 27, 2026, alleges misstatements about compliance with China Securities Regulatory Commission requirements, with a deadline of August 25, 2026. The Hub Group case, for shares bought between April 28, 2023 and May 11, 2026, concerns financial results, revenue recognition, and internal controls, and has a deadline of August 28, 2026. The Insulet action, for purchases between February 21, 2025 and May 26, 2026, involves manufacturing controls and procedures, with a deadline of August 31, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.
Insulet's Omnipod 5 momentum weighed against competitive and macro headwinds
Insulet is seeing strong momentum for its Omnipod 5 automated insulin delivery system, with total company revenues growing 30.1% in constant currency in the first quarter of 2026, driven by Omnipod revenue growth of 33%. The global customer base expanded nearly 25% year over year, and Omnipod 5 is now available in 19 countries. Management raised its 2026 outlook, forecasting total company revenue growth of 21-23% and adjusted EPS growth of more than 25%. However, the company faces intensifying competition and macroeconomic pressures, including incremental raw material and shipping costs tied to the Middle East conflict, which could limit operating margin expansion. The stock has lost 46.9% over the past year, and the Zacks Consensus Estimate for 2026 EPS remains unchanged at $6.46.
Deutsche Bank Initiates Insulet With Buy Rating and $190 Target
Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless insulin pump market with one of the strongest growth profiles in medical devices, and believes the stock has already discounted concerns about rising competition and pharmacy channel pressure. The analyst also considers fears over GLP-1 weight-loss drugs shrinking the insulin delivery market to be exaggerated and already reflected in the valuation.
Bronstein, Gewirtz & Grossman LLC Files Class Action Against Insulet Corporation
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Insulet Corporation and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Insulet securities between May 21, 2025 and May 26, 2026. The complaint claims that defendants made false and misleading statements about the company's business, operations, and compliance policies, specifically that manufacturing controls were defective, creating a foreseeable risk of safety violations or injury. Investors have until August 31, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.
The US FDA has classified a recall of certain Insulet Omnipod insulin pump systems as Class I, the most serious type. The recall affects specific lots of the Omnipod 5, Omnipod DASH, and Omnipod Eros devices. Insulet stated that pods in these lots may have a small tear in the cannula just above the skin, potentially causing insulin to leak and leading to under-delivery. As of May 20, Insulet reported 24 serious injuries and no deaths related to the issue.
Patient monitoring stocks beat Q1 revenue estimates by 2.3% but guidance disappoints
The four patient monitoring stocks tracked by this review reported a strong first quarter, with aggregate revenues beating analysts' consensus estimates by 2.3%, though next quarter's revenue guidance came in 0.8% below expectations. Insulet led the group with revenues of $761.7 million, up 33.9% year on year and exceeding estimates by 4.2%, while also posting the fastest revenue growth and biggest analyst estimate beat. iRhythm Technologies reported revenues of $199.4 million, up 25.7% year on year and beating estimates by 2.8%, and delivered the highest full-year guidance raise among its peers. ResMed posted revenues of $1.43 billion, up 10.8% year on year and exceeding estimates by 0.8%, but recorded the weakest performance against analyst estimates and slowest revenue growth in the group. DexCom reported revenues of $1.19 billion, up 15% year on year and topping estimates by 1.4%, though it had the weakest full-year guidance update among its peers.
Insulet Added to Russell 2500 Indexes, Appoints Former IDEXX CEO to Board
Insulet Corporation has been added to the Russell 2500 Index and the Russell 2500 Growth Benchmark, and has appointed former IDEXX Laboratories chief executive Jonathan Mazelsky as an independent director effective July 1, 2026. The index inclusions may attract passive fund inflows and broader institutional attention, while Mazelsky's healthcare and diagnostics background could influence the company's oversight and long-term strategy. These developments increase visibility but do not materially change near-term drivers, which remain Omnipod 5 uptake and algorithm enhancements, with product concentration and manufacturing execution as key risks.
Insulet Appoints Jay Mazelsky to Board of Directors
Insulet has appointed Jay Mazelsky to its Board of Directors. Mazelsky brings executive and board experience from IDEXX Laboratories and Philips Healthcare. The appointment adds healthcare technology and governance expertise to Insulet's boardroom. For investors following Insulet, a company focused on insulin delivery technology, board composition is an important part of the story. The addition of Jay Mazelsky connects Insulet with leadership experience from established healthcare and diagnostics companies, which may influence how it evaluates product priorities and operational decisions.
A $1000 Investment in Insulet 10 Years Ago Would Be Worth $5,389.63 Today
A $1000 investment in Insulet made in June 2016 would be worth $5,389.63 as of June 26, 2026, representing a gain of 438.96% excluding dividends but including price increases. Over the same period, the S&P 500 rose 261.12% and gold increased 193.20%. Insulet entered 2026 with strong momentum for its Omnipod 5 system in Type 1 and early Type 2 diabetes markets, and first-quarter results exceeded expectations, leading management to raise full-year revenue growth guidance. Shares have rallied 7.83% over the past four weeks, with seven upward earnings estimate revisions for fiscal 2026 and none lower.
Wall Street's Favorite Stocks: Insulet a Buy, Chewy and Alarm.com to Avoid
StockStory identifies Insulet as a stock where Wall Street's bullishness is justified, while recommending investors avoid Chewy and Alarm.com despite high consensus price targets. Insulet, maker of the Omnipod insulin delivery system, is favored for its steady constant currency growth, expanding free cash flow margin, and rising returns on capital. Chewy faces sluggish sales growth and low gross margins, while Alarm.com struggles with slowing demand and static operating margins. Insulet trades at 21.5 times forward earnings, Chewy at 7.9 times forward EV/EBITDA, and Alarm.com at 2.3 times forward price-to-sales.
Insulet Stands Out as a Mid-Cap Growth Pick While Genuine Parts and Deckers Face Headwinds
StockStory highlights Insulet as a mid-cap stock with massive growth potential while questioning Genuine Parts and Deckers. Insulet, with a market cap of $10.33 billion, posted constant currency growth averaging 26.8% over the past two years and saw its free cash flow margin jump by 25.8 percentage points over five years. In contrast, Genuine Parts, valued at $14.07 billion, recorded below-average annual revenue increases of 3.1% over three years and an operating margin of 4.5% that trails the industry. Deckers, at a $15.88 billion market cap, showed subpar constant currency growth and a forecasted 5.1 percentage point decline in free cash flow margin.
USA